Issue 37


Data Science Driving Innovation in Psychedelic Medicine

Big data has revolutionised healthcare, enhancing treatment safety, efficacy and operational efficiency. The technology has become crucial to accelerate drug discovery and development, underpinning the clinical trials that demonstrate psychedelic medicines’ groundbreaking potential.

Study results indicate significantly improved patient outcomes, which will instigate further investigations to treat associated disorders, with digital innovation a vehicle to drive the industry to new frontiers.

Looking Back on the PSYCH Investor Summit: Research & Development

The industry-leading global event series returned on 7 July, with the PSYCH Investor Summit: Research & Development delivering investor-focused panel discussions, professional networking opportunities, research updates and company presentations.

Clinical trials are demonstrating the safety and efficacy of psychedelic medicines at an unprecedented rate, creating opportunities for stakeholders across the burgeoning sector. With subject-matter experts presenting the latest data and innovation driving the industry to new frontiers, the summit has empowered operators, regulators and investors to make informed decisions and map the future of the space.

ATAI LIFE SCIENCES FOUNDER WARNS DECRIMINALISATION COULD SET BACK REGULATION

Christian Angermayer debated the socioeconomic benefits of legalisation at the PSYCH Investor Summit on 7 July.

READ MORE

HEALTH CANADA APPROVES NUMINUS AND MAPS STUDY TO TREAT PTSD WITH MDMA

Canada’s regulator has endorsed another study into MDMA-assisted therapy as the country looks to adopt the breakthrough treatment.

READ MORE

BUSINESS & INVESTMENT


Cybin expands European operations and provides IP update.


Wesana Health to acquire PsyTech.


Havn Life signs supply agreement with Cube Psytech.


Mynd Life Sciences expands IP portfolio.


PsyBio Therapeutics files patent for tryptamine combination.


Mindcure files patent for ibogaine-based compound.


Red Light Holland provides updates on sales and distribution.


MindMed partners with Datavant for data connectivity.


Cybin files 13th patent application and builds digital therapeutics strategy.


Silo Wellness approved to trade on the OTCQB under SILFF.


Horizons ETFs rebalances psychedelics ETF.


Ketamine One announces interim CEO.


Delix Therapeutics appoints new CSO and CIO.


Psyched Wellness appoints Amanda Galbraith to its board of directors.


Awakn Life Sciences creates preclinical and clinical advisory boards.

RESEARCH & SCIENCE


Mindset Pharma releases preclinical results data for psilocybin-derivative MSP-1014.


Tryp Therapeutics partners with University of Michigan to study treatment formulations.


Awakn life Sciences creates research programme for ketamine therapies.


Wired speaks with Amanda Feilding, Founder of the Beckley Foundation.


Novamind to be the research site for Bionomics’ PTSD trial.


Lexston Life Sciences exemption for psychedelic research sent to government office for review.

REGULATION & LEGISLATION


California’s Public Health Committee approves psychedelic decriminalisation bill.


Canadian municipalities urge government to federally decriminalise drugs.


Colorado bill to limit paramedic use of ketamine.


Decriminalize Nature event to advocate for decriminilisation in Grand Rapids, MI.


Rhode Island approves harm-reduction centres for drug consumption.